Finland's Orion eyes US sales boost with blockbuster prostate cancer drug
By Anne Kauranen
HELSINKI, Sept 26 (Reuters) -Finnish drugmaker Orion ORNBV.HE wants to boost sales in the United States on the back of the success of its prostate cancer drug Nubeqa, which it is developing jointly with German partner Bayer BAYGn.DE, Orion's chief executive Liisa Hurme told Reuters.
The two companies announced on Thursday that sales of Nubeqa have been worth more than a billion euros this year, making it Orion's first "blockbuster" product, and that Bayer is seeking approval from U.S. authorities to expand its use to a new patient group.
Nubeqa, also known as darolutamide, is Bayer's third best selling drug globally with sales growing most rapidly in the U.S., Hurme said.
That encouraged Orion to establish a research centre in the U.S. last year, with an eye on growth opportunities in a country that accounts for roughly half of the world's drug market, Hurme said.
"We are in the U.S. in order to develop our own innovations in that market ourselves," she said, referring to Orion's ODM-111 molecule for pain treatment and Orion's cooperation with U.S. based drugmaker Merck & Co MRK.N in the development of opevesostat, used against metastatic castration-resistant prostate cancer, among other products.
"Pain is highly undertreated and especially in the U.S., the use of opiates is a major problem," she added, referring to the expansion of drug misuse.
Bayer said it was submitting an application to the U.S. Food and Drug administration for a third indication for darolutamide to be used in combination with androgen deprivation therapy in patients with metastatic hormone-sensitive prostate cancer, following a successful phase III trial.
Reporting by Anne Kauranen; Editing by Kirsten Donovan
Related Assets
Latest News
Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.
All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.
Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.
